FDA's 2026 Single-Trial Default Standard Reshapes Dual-Pivotal Debate for Sponsors
核心洞察
FDA has set one adequate and well-controlled trial plus confirmatory evidence as the default standard for drug approvals, displacing the two-trial assumption many Phase 3 programs were built on.
A single pivotal trial meeting 21 CFR 314.126 remains necessary, and FDA paired the default with a plausible mechanism framework for individualized therapies.
Oncology, rare disease and precision medicine sponsors gain most, while EMA's CHMP (搜索) still treats randomised controlled evidence as the efficacy standard for marketing authorisation.
FDA has announced that one adequate and well-controlled clinical trial combined with confirmatory evidence will serve as the new default standard for all drug approvals, according to a regulatory analysis. The change lands while a substantial share of Phase 3 programs in active development were scoped, powered and budgeted against a two-trial assumption. Sponsors who set that assumption last year did not misjudge the position at the time, but they may now be carrying excess trial infrastructure the current regulatory posture no longer requires.
The Nature Reviews Drug Discovery analysis, titled "Two trials or not two trials? That should not be the question," argues the field has been optimizing for a structural requirement, two adequate and well-controlled studies, rather than the evidentiary threshold those trials were meant to satisfy: replicable demonstration of a treatment effect with controlled error rates. Under FDA's posture, a single pivotal trial meeting the adequate and well-controlled standard under 21 CFR 314.126 remains necessary, but sponsors no longer face an automatic expectation of a second independent replication study before NDA submission. The confirmatory evidence requirement fills that gap, and FDA paired the default with a plausible mechanism framework governing how mechanistic or biological data can serve confirmatory functions for individualized therapies. FDA had not published guidance specifying which confirmatory evidence types satisfy the default across indication classes.
Oncology, rare disease and precision medicine sponsors gain the most direct benefit, where enrollment is constrained and biological rationale is often robust. Broad-population sponsors face a more nuanced calculus, since reviewers have historically demanded replication as protection against type I error inflation. FDA's March 2024 webinar on integrated safety analyses identified Type C meetings as the venue to align the integrated safety analysis plan before data lock, and a single-trial architecture yields a thinner safety database than two trials combined. EMA's CHMP (搜索) has maintained that randomised controlled evidence remains the standard for efficacy, positioning single-arm pivotal trials as an exception, and its conditional marketing authorisation route defers confirmatory evidence to post-approval with binding commitments rather than requiring it in the NDA package. A 2022 JAMA Network Open economic evaluation found a single platform trial evaluating 10 interventions cost substantially less and completed faster than a series of conventional two-group trials. Sponsors with Phase 2 readouts expected in Q4 2026 or Q1 2027 face the most acute decision, since the trial count embedded in a Phase 3 protocol is difficult to revise once FDA has reviewed the IND amendment containing it.